|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
4
|
|
pubmed:dateCreated |
2010-8-13
|
|
pubmed:abstractText |
The concept of metronomic chronic administration of low-dose chemotherapy has become relevant for the treatment of cancer in the last several years. This study sought to determine the safety and activity of oral vinorelbine (VNB), using a metronomic schedule of administration, in elderly patients with metastatic breast cancer (MBC).
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
IM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Aug
|
|
pubmed:issn |
1938-0666
|
|
pubmed:author |
pubmed-author:AbbruzzeseAlbertoA,
pubmed-author:AddeoRaffaeleR,
pubmed-author:BottiGerardoG,
pubmed-author:CapassoElenaE,
pubmed-author:CaragliaMicheleM,
pubmed-author:CennamoGregorioG,
pubmed-author:Del PreteSalvatoreS,
pubmed-author:FaiolaVincenzoV,
pubmed-author:LympJamesJ,
pubmed-author:MontellaLilianaL,
pubmed-author:SgambatoAlessandroA
|
|
pubmed:issnType |
Electronic
|
|
pubmed:day |
1
|
|
pubmed:volume |
10
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
301-6
|
|
pubmed:meshHeading |
pubmed-meshheading:20705563-Administration, Oral,
pubmed-meshheading:20705563-Aged,
pubmed-meshheading:20705563-Aged, 80 and over,
pubmed-meshheading:20705563-Antineoplastic Agents, Phytogenic,
pubmed-meshheading:20705563-Breast Neoplasms,
pubmed-meshheading:20705563-Disease-Free Survival,
pubmed-meshheading:20705563-Drug Administration Schedule,
pubmed-meshheading:20705563-Female,
pubmed-meshheading:20705563-Humans,
pubmed-meshheading:20705563-Kaplan-Meier Estimate,
pubmed-meshheading:20705563-Vinblastine
|
|
pubmed:year |
2010
|
|
pubmed:articleTitle |
Low-dose metronomic oral administration of vinorelbine in the first-line treatment of elderly patients with metastatic breast cancer.
|
|
pubmed:affiliation |
Dipartimento di Oncologia, S Giovanni di Dio Hospital, Frattaminore, Naples, Italy.
|
|
pubmed:publicationType |
Journal Article,
Research Support, Non-U.S. Gov't,
Clinical Trial, Phase II
|
